+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tumor Antigen"

From
B7-H3-Targeted Immunotherapy: a Competitor Analysis - Product Thumbnail Image

B7-H3-Targeted Immunotherapy: a Competitor Analysis

  • Report
  • February 2026
  • Global
From
From
From
From
CAR T - Cell Therapy - Competitive landscape, 2023 - Product Thumbnail Image

CAR T - Cell Therapy - Competitive landscape, 2023

  • Report
  • April 2023
  • 500 Pages
  • Global
From
From
Bispecific Antibody & Cancer Patent Landscape Analysis - Product Thumbnail Image

Bispecific Antibody & Cancer Patent Landscape Analysis

  • Report
  • January 2025
  • 120 Pages
  • Global
Clinical Immuno-Oncology - Product Thumbnail Image

Clinical Immuno-Oncology

  • Book
  • June 2023
Loading Indicator

The Tumor Antigen market is a subset of the Oncology Drugs market, which focuses on the development of drugs to treat cancer. Tumor antigens are molecules that are expressed on the surface of cancer cells and can be recognized by the immune system. These antigens can be used to develop drugs that target and destroy cancer cells, while leaving healthy cells unharmed. Tumor antigens can be used to develop vaccines, monoclonal antibodies, and other immunotherapies. These therapies can be used to treat a variety of cancers, including breast, lung, and colorectal cancer. Some companies in the Tumor Antigen market include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Roche. These companies are actively researching and developing new treatments for cancer, including immunotherapies that target tumor antigens. Show Less Read more